Following the release of a joint statement1 from leading psychiatric organizations voicing concern over Executive Order 14212, Psychiatric Times spoke with its Editor-in-Chief, John J. Miller, MD, to discuss the implications of this federal directive and the response from the psychiatric community.
The executive order, issued on February 13, 2025,2 called for an assessment of selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, and stimulants, raising concerns among psychiatrists that it could fuel misinformation and limit access to essential treatments. Miller emphasized the lack of respect for the overwhelming scientific evidence supporting these medications when they are appropriate.
“The executive order came as quite a surprise and is quite concerning to myself and many of my colleagues, if…